|View printer-friendly version|
ASLAN Pharmaceuticals Presents Late-Breaking Data From Phase 2 Study in China Testing Varlitinib in Second Line Biliary Tract Cancer at CSCO
- Biliary tract cancer (BTC) patients treated with varlitinib plus capecitabine in second line achieved a response rate of 11% including two complete responses, median PFS of 2.7 months and OS of 5.8 months
- Patients on study appeared to present with more aggressive disease as only 10% of patients responded to first line gemcitabine-based treatment prior to enrolment
The phase 2 study, which was closed before the completion of recruitment as previously announced, enrolled 62 patients in mainland
ASLAN previously reported that patients enrolled into this study appeared to have performed significantly worse, prior to recruitment, in the first line setting than observed in published global studies, suggesting that patients in
Professor Qin Shukui, Deputy Director of People’s Liberation Army 81 Hospital (
Enrolment in a global pivotal study of varlitinib in second line BTC, the TreeTopp (TREatmEnT OPPortunity) study, was completed ahead of schedule in
A copy of the abstract, titled: “JADETREE*: A phase 2A, single arm, multicenter, study of the panHER inhibitorvarlitinib plus capecitabine in Chinese patients with advanced or metastatic biliary tract cancer (BTC),” is available on ASLAN’s website (www.aslanpharma.com).
Media and IR contacts
About varlitinib (ASLAN001)
Varlitinib (ASLAN001) is a highly potent, oral, reversible, small molecule pan-HER inhibitor that targets the human epidermal growth factor receptors HER1, HER2 and HER4. These receptors can be mutated or overexpressed in many tumours, which can cause excessive proliferative activity and uncontrolled growth. Therefore, by inhibiting the activation of the HER receptors, varlitinib could inhibit proliferation and control tumour growth. Varlitinib has been granted orphan drug designation in
Forward looking statements
This release contains forward-looking statements. These statements are based on the current beliefs and expectations of the management of
All statements other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan,” or the negative of those terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify estimates, projections and other forward-looking statements. Estimates, projections and other forward-looking statements speak only as of the date they were made, and, except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection or forward-looking statement.
Source: ASLAN PHARMACEUTICALS LIMITED